| NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 16729-0332-05 | 16729-0332 | OXALIPLATIN | OXALIPLATIN | 5.0 mg/mL | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | May 17, 2018 | In Use | |
| 51862-0086-51 | 51862-0086 | Temozolomide | Temozolomide | 140.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Oct 10, 2016 | Mar 31, 2019 | In Use |
| 81927-0201-01 | 81927-0201 | Imatinib oral | IMKELDI | 80.0 mg/mL | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Dec 19, 2024 | In Use | |
| 70710-1741-06 | 70710-1741 | Dasatinib | Dasatinib | 20.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Mar 3, 2025 | In Use | |
| 81927-0204-01 | 81927-0204 | Methotrexate | JYLAMVO | 2.0 mg/mL | Chemotherapy | Antimetabolite | Folic Acid Analog | Oral | Dec 15, 2023 | In Use | |
| 24338-0341-05 | 24338-0341 | Lomustine | Gleostine | 40.0 mg/1 | Chemotherapy | Alkylating Agent | Nitrosourea | Oral | Oct 24, 2025 | In Use | |
| 00143-9307-01 | 00143-9307 | Idarubicin Hydrochloride | Idarubicin Hydrochloride | 1.0 mg/mL | Chemotherapy | Antitumor Antibiotic | Anthracycline | Intravenous | Jan 12, 2018 | In Use | |
| 50419-0171-03 | 50419-0171 | Regorafenib | Stivarga | 40.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGF, FGF, PDGFR, KIT, RET, TIE2, DDR2, TrkQ, RAF, BRAF, SAPK2, PTK, Abl | Oral | Sep 27, 2012 | In Use | |
| 63323-0750-20 | 63323-0750 | Oxaliplatin | Oxaliplatin | 5.0 mg/mL | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | Jun 11, 2010 | In Use | |
| 62332-0622-50 | 62332-0622 | Paclitaxel | Paclitaxel | 6.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Oct 20, 2022 | In Use | |
| 81864-0101-30 | 81864-0101 | Momelotinib | Ojjaara | 200.0 mg/1 | Chemotherapy | Enzyme Inhibitor | JAK 1/2 | Oral | Sep 15, 2023 | In Use | |
| 59651-0204-60 | 59651-0204 | Capecitabine | Capecitabine | 150.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Oral | Apr 17, 2018 | In Use | |
| 63323-0650-20 | 63323-0650 | Oxaliplatin | Oxaliplatin | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | Jun 11, 2010 | May 21, 2015 | No Longer Used | |
| 16729-0229-03 | 16729-0229 | Pemetrexed | Pemetrexed | 100.0 mg/4mL | Chemotherapy | Antimetabolite | Folic Acid Analog | Intravenous | May 25, 2022 | In Use | |
| 81298-8112-01 | 81298-8112 | Cyclophosphamide | Cyclophosphamide | 1.0 g/50mL | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Intravenous, Oral | Jan 1, 2022 | In Use | |
| 63323-0104-50 | 63323-0104 | Etoposide | Etoposide | 20.0 mg/mL | Chemotherapy | Plant Alkaloid | Epipodophyllotoxins | Intravenous | Jul 18, 2001 | In Use | |
| 81298-3890-01 | 81298-3890 | Eribulin Mesylate | Eribulin Mesylate | 0.5 mg/mL | Chemotherapy | Antimitotic Agent | Furopyrans | Intravenous | Jul 22, 2024 | In Use | |
| 25021-0223-20 | 25021-0223 | Cytarabine | Cytarabine | 100.0 mg/mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intrathecal, Intravenous, Subcutaneous | Jun 1, 2023 | In Use | |
| 00069-0145-01 | 00069-0145 | Axitinib | Inlyta | 1.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR | Oral | Jan 27, 2012 | In Use | |
| 81607-0005-11 | 81607-0005 | Arsenic trioxide | ARSENIC TRIOXIDE | 1.0 mg/mL | Chemotherapy | Miscellaneous Agent | PML/RARa | Intravenous | May 31, 2023 | In Use | |
| 25021-0253-50 | 25021-0253 | Cisplatin | Cisplatin | 1.0 mg/mL | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | Jul 1, 2023 | In Use | |
| 67877-0539-07 | 67877-0539 | Temozolomide | Temozolomide | 100.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Apr 28, 2017 | In Use | |
| 00703-4183-01 | 00703-4183 | Vinorelbine | Vinorelbine | 50.0 mg/5mL | Chemotherapy | Antimitotic Agent | Vinca Alkaloid | Intravenous | Mar 1, 2003 | Apr 30, 2013 | No Longer Used |
| 16714-0726-01 | 16714-0726 | Irinotecan Hydrochloride | Irinotecan Hydrochloride | 20.0 mg/mL | Chemotherapy | Topoisomerase I Inhibitor | Camptothecin Analogs | Intravenous | Jun 15, 2017 | Apr 30, 2020 | In Use |
| 69339-0229-05 | 69339-0229 | Paclitaxel | Paclitaxel | 6.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Nov 7, 2024 | Jan 18, 2025 | In Use |
Found 12250 results — Export these results
Home